CU6 · ASX

Clarity Pharmaceuticals Ltd. (ASX:CU6)

AU$3.46

 0.01 (0.29%)
ASX:Live
17/09/2025 04:10:28 PM
Hammer Bearish HALO Small HALO Ords HALO Consensus Value HALO 200 +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CU6 Overview

CU6 Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Very Weak

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

About CU6

Website

N/A

Telephone

61.2.9209.4037

Address

4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015

Description

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.

CU6 Price Chart

Key Stats

Market Cap

AU$1.28B

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.43 - 8.98

Trade Value (12mth)

AU$2,419,414.00

1 week

10.22%

1 month

-5.74%

YTD

-15.02%

1 year

-54.06%

All time high

8.98

Key Fundamentals

EPS 3 yr Growth

110.70%

EBITDA Margin

N/A

Operating Cashflow

-$55m

Free Cash Flow Return

-46.30%

ROIC

-54.40%

Interest Coverage

N/A

Quick Ratio

9.70

Other Data

Shares on Issue (Fully Dilluted)

321m

HALO Sector

Healthcare

Next Company Report Date

26-Aug-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CU6 Announcements

Latest Announcements

Date Announcements

12 September 25

Becoming a substantial holder

×

Becoming a substantial holder

09 September 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

05 September 25

Annual Report to shareholders

×

Annual Report to shareholders

05 September 25

Appendix 4G

×

Appendix 4G

05 September 25

Corporate Governance Statement

×

Corporate Governance Statement

05 September 25

S&P DJI Announces September 2025 Quarterly Rebalance

×

S&P DJI Announces September 2025 Quarterly Rebalance

03 September 25

Becoming a substantial holder

×

Becoming a substantial holder

02 September 25

Change in substantial holding

×

Change in substantial holding

28 August 25

Preliminary Final Report

×

Preliminary Final Report

11 August 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

11 August 25

Cleansing Notice

×

Cleansing Notice

08 August 25

Change in substantial holding

×

Change in substantial holding

04 August 25

Notification regarding unquoted securities - CU6

×

Notification regarding unquoted securities - CU6

04 August 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

04 August 25

Cleansing Notice

×

Cleansing Notice

01 August 25

Cleansing Notice

×

Cleansing Notice

01 August 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

01 August 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

01 August 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

31 July 25

Application for quotation of securities - CU6

×

Application for quotation of securities - CU6

31 July 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 July 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

29 July 25

Becoming a substantial holder

×

Becoming a substantial holder

28 July 25

Clarity successfully completes $203 million institutional pl

×

Clarity successfully completes $203 million institutional pl

28 July 25

Proposed issue of securities - CU6

×

Proposed issue of securities - CU6

24 July 25

Change in substantial holding

×

Change in substantial holding

CU6 Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.09 -0.15 -0.20 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.09 -0.15 -0.20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.2 -63.9 -30.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.09 -0.12 -0.18 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.11 -0.16 -0.17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -54.0 -37.1 -47.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -15.2 -3.0 -6.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.26 0.47 0.28 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.26 0.47 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.8 77.4 -40.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 260 273 319 Lock Lock Lock
Basic m Lock Lock Lock Lock 260 273 319 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 36 56 78 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -117.3 -52.3 -20.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -36 -56 -78 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.9 -55.7 -39.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -36 -56 -79 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.0 -55.7 -39.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -34 -54 -73 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -10 -11 -9 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -25 -42 -64 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3.6 -72.0 -51.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -27 -43 -55 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 3 -55 52 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 115 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -28 -44 -55 Lock Lock Lock
     Growth % Lock Lock Lock Lock -103.6 -58.8 -25.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 65 137 84 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 77 155 101 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -65 -137 -84 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 8 11 Lock Lock Lock
Equity $m Lock Lock Lock Lock 69 146 90 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 69 146 90 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.0 111.5 -38.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -32.0 -27.4 -63.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.6 -28.9 -71.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -44.8 -52.3 -66.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -30.5 -39.3 -54.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -34.1 -40.1 -46.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.8 2.4 1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.0 -93.3 -93.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.2 19.0 9.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.2 19.0 9.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.8 88.6 83.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -364.6 -534.5 -527.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -32.0 -27.4 -63.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.6 -28.9 -71.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -35.6 -28.9 -71.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 10,339.9 5,877.6 5,214.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -10,339.9 -5,877.6 -5,214.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

6.95%

Value ($M)

86

Prior Change

-0.30%

7 Day Change

N/A

1 Month Change

0.70%

3 Month Change

-0.70%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CU6 Shortsell

Frequently Asked Questions

The current share price of Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$3.46.
The 52-week high share price for Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$8.98.
The 52-week low share price for Clarity Pharmaceuticals Ltd. (CU6:ASX)? is AU$1.43.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) has a franking level of 0.0%.
Clarity Pharmaceuticals Ltd. (CU6:ASX) is classified in the Healthcare.
The current P/E ratio for Clarity Pharmaceuticals Ltd. (CU6:ASX) is .
The current share price of Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$3.46.
The 52-week high share price for Clarity Pharmaceuticals Ltd. (CU6:ASX) is AU$8.98.
The 52-week low share price for Clarity Pharmaceuticals Ltd. (CU6:ASX)? is AU$1.43.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) does not pay a dividend.
Clarity Pharmaceuticals Ltd. (CU6:ASX) has a franking level of 0.0%.
Clarity Pharmaceuticals Ltd. (CU6:ASX) is classified in the Healthcare.
The current P/E ratio for Clarity Pharmaceuticals Ltd. (CU6:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.